Zudaw
Zudaw Uses, Dosage, Side Effects, Food Interaction and all others data.
Zudaw blocks dopamine receptors and in higher doses, it also blocks serotonin receptors in chemoreceptor trigger zone of the CNS. It enhances the response to acetylcholine of tissue in upper GI tract causing enhanced motility and accelerated gastric emptying w/o stimulating gastric, biliary, or pancreatic secretions. It also increases lower esophageal sphincter tone.
Zudaw increases gastric emptying by decreasing lower esophageal sphincter (LES) pressure. It also exerts effects on the area postrema of the brain, preventing and relieving the symptoms of nausea and vomiting. In addition, this drug increases gastrointestinal motility without increasing biliary, gastric, or pancreatic secretions.
Because of its antidopaminergic activity, metoclopramide can cause symptoms of tardive dyskinesia (TD), dystonia, and akathisia, and should therefore not be administered for longer than 12 weeks.
Trade Name | Zudaw |
Availability | Prescription only |
Generic | Metoclopramide |
Metoclopramide Other Names | Metoclopramida, Metoclopramide, Metoclopramidum |
Related Drugs | Ubrelvy, Botox, omeprazole, famotidine, pantoprazole, hydroxyzine, diclofenac, lorazepam, ondansetron, Zofran |
Type | |
Formula | C14H22ClN3O2 |
Weight | Average: 299.796 Monoisotopic: 299.14005467 |
Protein binding | Metoclopramide is 30% bound to plasma proteins, mainly to alpha-1-acid glycoprotein. |
Groups | Approved, Investigational |
Therapeutic Class | Anti-emetic drugs, Prokinetic drugs |
Manufacturer | |
Available Country | Taiwan |
Last Updated: | September 19, 2023 at 7:00 am |
![Zudaw Zudaw](https://www.medicinesfaq.com/media/png/zudaw.png)
Uses
Intubation of the small intestine, Premedication for radiologic examination of the upper gastrointestinal tract, Prophylaxis of chemotherapy-induced nausea and vomiting, Nausea and vomiting associated with cancer chemotherapy or radiotherapy, Diabetic gastric stasis, Gastro-oesophageal reflux disease, Diabetic gastric stasis, Prophylaxis of postoperative nausea and vomiting
Zudaw is also used to associated treatment for these conditions: Chemotherapy-Induced Nausea and Vomiting (CINV), Diabetic Gastroparesis, Dyspepsia, Flatulence, Gastroesophageal Reflux, Gastroparesis, Hiccups, Hyperacidity, Migraine, Nausea and vomiting, Post Operative Nausea and Vomiting (PONV), Acute, recurrent Diabetic Gastroparesis, Gastric bezoar, Radiation therapy induced nausea and vomiting, Facilitation of small bowel intubation therapy, Gastric emptying for radiologic procedures
How Zudaw works
Zudaw causes antiemetic effects by inhibiting dopamine D2 and serotonin 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) located in the area postrema of the brain. Administration of this drug leads to prokinetic effects via inhibitory actions on presynaptic and postsynaptic D2 receptors, agonism of serotonin 5-HT4 receptors, and antagonism of muscarinic receptor inhibition. This action enhances the release of acetylcholine, causing increased lower esophageal sphincter (LES) and gastric tone, accelerating gastric emptying and transit through the gut. Zudaw antagonizes the dopamine D2 receptors. Dopamine exerts relaxant effect on the gastrointestinal tract through binding to muscular D2 receptors.
Dosage
Zudaw dosage
Intravenous-Intubation of the small intestine, Premedication for radiologic examination of the upper gastrointestinal tract:
- Adult: 10 mg as a single dose by slow inj over 1-2 min.
- Child: <6 yr 0.1 mg/kg as a single dose; 6-14 yr 2.5-5 mg as a single dose.
Prophylaxis of chemotherapy-induced nausea and vomiting:
- Adult: For highly emetogenic drugs/regimens: Initially, 2 mg/kg by slow inj over at least 15 min, 30 min before chemotherapy. Repeat 2 hrly for 2 doses, then 3 hrly for 3 doses. For less emetogenic drugs/regimens: 1 mg/kg may be used. Max duration: 5 days.
Oral-
Nausea and vomiting associated with cancer chemotherapy or radiotherapy:
- Adult: 10 mg, up to tid. Max duration: 5 days.
Diabetic gastric stasis:
- Adult: 10 mg 4 times daily for 2-8 wk.
Gastro-oesophageal reflux disease:
- Adult: 10-15 mg 4 times daily, depending on severity of symptoms. If symptoms are intermittent, may give single doses of 20 mg prior to provoking situation. Max duration: 12 wk.
- Elderly: 5 mg/dose.
Parenteral-
Diabetic gastric stasis:
- Adult: 10 mg 4 times daily by IM inj or slow IV inj over 1-2 min for up to 10 days. Convert to oral admin when symptoms subside sufficiently.
Prophylaxis of postoperative nausea and vomiting:
- Adult: 10 mg as a single dose by IM or slow IV inj over at least 3 min.
- Child: 1-3 yr 10-14 kg: 1 mg tid; >3-5 yr 15-19 kg: 2 mg tid; >5-9 yr 20-29 kg: 2.5 mg tid; >9-18 yr 30-60 kg: 5 mg tid. Max duration: 48 hr.
Should be taken on an empty stomach. Take ½ hr before meals.
Side Effects
Extrapyramidal symptoms (usually acute dystonic reactions); parkinsonism; tardive dyskinesia; restlessness, drowsiness, dizziness, anxiety, confusion, tremor; hallucinations (rare); depression w/ suicidal ideation; hypotension, HTN, GI disturbances, dyspnoea, visual disturbances, urinary frequency and incontinence, headache; hypersensitivity reactions (rash, bronchospasm, angioedema); galactorrhoea or related disorders; blood disorders; transient increase in plasma-aldosterone concentration. IV: Cardiac conduction disorders, transient flushing of face and upper body (high dose).
Toxicity
The rat oral LD50 of metoclopramide is 750 mg/kg.
Some symptoms of an overdose with metoclopramide include drowsiness, disorientation, and extrapyramidal reactions. Drugs that manage Parkinson's disease or anticholinergic drugs or antihistamines with anticholinergic properties should be employed to treat extrapyramidal symptoms. Normally, these symptoms subside within 24 hours. Unintentional overdose in infants receiving the oral solution of metoclopramide resulted in seizures, extrapyramidal symptoms, in addition to a lethargic state.
In addition, methemoglobinemia has been found to occur in premature and full-term neonates after a metoclopramide overdose. Intravenous methylene blue may treat metoclopramide-associated methemoglobinemia. It is important to note that methylene blue administration may lead to hemolytic anemia in patients who suffer from G6PD deficiency, which can result in fatality. Dialysis has not been shown to be effective in sufficiently eliminating metoclopramide in an overdose situation due to low plasma distribution of this drug.
Precaution
Patients with underlying neurological conditions, cardiac conduction disturbances, uncorrected electrolyte imbalance, bradycardia. Renal and hepatic impairment. Elderly, childn. Pregnancy and lactation.
Interaction
Antagonistic effect with anticholinergics and morphine derivatives. Potentiation of sedative effects with CNS depressants. Additive effect with other neuroleptics on the occurrence of extrapyramydal disorders. May increase the risk of serotonin syndrome with serotonergic drugs (e.g. SSRIs). May decrease digoxin bioavailability. May increase ciclosporin bioavailability. May prolong the neuromuscular blocking effect of mivacurium and suxamethonium. Increased exposure levels with strong CYP2D6 inhibitors (e.g. fluoxetine). May reduce plasma concentration of atovaquone.
Food Interaction
- Avoid alcohol.
- Take before a meal. Co-administration with food decreases bioavailability - take 30 minutes before meals.
[Moderate] GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.
Use in combination may result in additive central nervous system depression and
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.
Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
Zudaw Hypertension interaction
[Moderate] In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.
Therapy with metoclopramide should be administered cautiously in patients with hypertension because of potential increases in blood pressure.
Zudaw Drug Interaction
Moderate: diphenhydramine, duloxetine, pregabalin, alprazolamMinor: aspirin, acetaminophen, acetaminophenUnknown: omega-3 polyunsaturated fatty acids, insulin glargine, furosemide, atorvastatin, metoprolol, metoprolol, polyethylene glycol 3350, esomeprazole, montelukast, cyanocobalamin, ascorbic acid, cholecalciferol, ondansetron
Zudaw Disease Interaction
Major: depression, gastrointestinal disorders, NMS, pheochromocytoma, seizures, tardive dyskinesiaModerate: fluid retention, hypertension, parkinsonism, renal dysfunction
Volume of Distribution
The volume of distribution of metoclopramide is approximately 3.5 L/kg. This implies a high level of tissue distribution. Zudaw crosses the placental barrier and can cause extrapyramidal symptoms in the fetus.
Elimination Route
Zudaw is rapidly absorbed in the gastrointestinal tract with an absorption rate of about 84%. The bioavailability of the oral preparation is reported to be about 40.7%, but can range from 30-100%.
Nasal metoclopramide is 47% bioavailable. A 15mg dose reaches a Cmax of 41.0 ng/mL, with a Tmax of 1.25 h, and an AUC of 367 ng*h/mL.
Half Life
The mean elimination half-life of metoclopramide in people with healthy renal function ranges from 5 to 6 hours but is prolonged in patients with renal impairment. Downward dose adjustment should be considered.
Clearance
The renal clearance of metoclopramide is 0.16 L/h/kg with a total clearance of 0.7 L/h/kg. Clinical studies showed that the clearance of metoclopramide may be reduced by up to 50% in patients with renal impairment. After high intravenous doses, total metoclopramide clearance ranged from 0.31 to 0.69 L/kg/h.
Elimination Route
About 85% of an orally administered dose was measured in the urine within 72 hours during a pharmacokinetic study. An average of 18% to 22% of 10-20 mg dose was recovered as free drug within 3 days of administration.
Pregnancy & Breastfeeding use
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Contraindication
GI haemorrhage, mechanical obstruction or GI perforation; confirmed or suspected pheochromocytoma; history of neuroleptic or metoclopramide-induced tardive dyskinesia; epilepsy, Parkinson's disease; history of methaemoglobinaemia with metoclopramide or of NADH cytochrome-b5 deficiency. Concomitant use with levodopa or dopaminergic agonists.
Acute Overdose
Symptoms: Extrapyramidal disorders, drowsiness, decreased level of consciousness, confusion, hallucination, cardiorespiratory arrest.
Management: Symptomatic treatment with continuous monitoring of CV and resp functions. In case of extrapyramidal symptoms, treatment is symptomatic (benzodiazepines in childn and/or anticholinergic antiparkinsonian medicinal products in adults).
Storage Condition
Store between 20-25°C. Protect from light.
Innovators Monograph
You find simplified version here Zudaw
Zudaw contains Metoclopramide see full prescribing information from innovator Zudaw Monograph, Zudaw MSDS, Zudaw FDA label
FAQ
What is Zudaw used for?
Zudaw is a medication used for stomach and esophageal problems. It is commonly used to treat and prevent nausea and vomiting, to help with emptying of the stomach in people with delayed stomach emptying, and to help with gastroesophageal reflux disease. It is also used to treat migraine headaches.
How safe is Zudaw ?
Older adults should not usually take Zudaw , unless it is used to treat slow stomach emptying, because it is not as safe or effective as other medications that can be used to treat those conditions.
How does Zudaw work?
Older adults should not usually take Zudaw, unless it is used to treat slow stomach emptying, because it is not as safe or effective as other medications that can be used to treat those conditions.
What are the common side effects of Zudaw?
Common side effects of Zudaw are include:
- drowsiness
- excessive tiredness
- weakness
- headache
- dizziness
- diarrhea
- nausea
- vomiting
- breast enlargement or discharge
- missed menstrual period
- decreased sexual ability
- frequent urination
- inability to control urination
Is Zudaw safe during pregnancy?
The study also found no increased risk of miscarriage, stillbirth, preterm birth, low birth weight or fetal growth restriction associated with metoclopramide use in pregnancy.
Why is Zudaw used in pregnancy?
Nausea and vomiting are very common during pregnancy, mainly throughout the first trimester. Zudaw is a dopamine receptor blocking drug that is commonly used to treat nausea and vomiting.
Can I drink alcohol with Zudaw?
Avoid drinking alcohol with Zudaw. It will make you feel more sleepy.
When should be taken of Zudaw?
Zudaw is usually taken 4 times a day on an empty stomach, 30 minutes before each meal and at bedtime.
How long does Zudaw take to work?
Zudaw tablets and liquid usually start to work after 30 to 60 minutes.
How long does Zudaw stay in my system?
The onset of pharmacological action of Zudaw is 1 to 3 minutes following an intravenous dose, 10 to 15 minutes following intramuscular administration, and 30 to 60 minutes following an oral dose; pharmacological effects persist for 1 to 2 hours.
How much dose of Zudaw can I take in a day?
The usual adult dose is 10mg, taken up to 3 times a day. Your doctor may recommend a dose of up to 30mg, if needed.
What happens if I take too much Zudaw?
If you take too much you could have dangerous levels of the drug in your body. Symptoms of an overdose of metoclopramide can include: drowsiness, confusion.
How long can I take Zudaw for?
Zudaw is usually only prescribed short term. You will generally take it for up to 5 days maximum. For migraine you will only take it when you have symptoms.
Is Zudaw bad for my liver?
Zudaw has been listed as a cause of clinically apparent liver injury in several large series of drug induced liver disease, but without documentation of the nature of the injury or degree of causality assessment.
What happens when I stop taking Zudaw ?
Continue to take Zudaw even if you feel well. Do not stop taking Zudaw without talking to your doctor. You may experience withdrawal symptoms such as dizziness, nervousness, and headaches when you stop taking Zudaw.
Does Zudaw affect blood pressure?
Your blood pressure might get too high while you are using this Zudaw.
What happens if I miss a dose?
Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.
What happens if I overdose?
Seek emergency medical attention. Overdose symptoms may include drowsiness, confusion, or uncontrolled muscle movements.
Will Zudaw affect my fertility?
Studies have not suggested that Zudaw would affect fertility.
Is Zudaw safe for kidney disease?
Since Zudaw is excreted principally through the kidneys, in those patients whose creatinine clearance is below 40 mL/min, therapy should be initiated at approximately one-half the recommended dosage.